Viridian Therapeutics Inc
VRDN · NASDAQ
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.
ESG Scores
Overall ESG6.8
Environmental7.3
Social3.6
Governance6.1
Gender Diversity
Female Directors0.4%
CEO GenderMale